<?xml version='1.0' encoding='UTF-8'?>
<extracted-tables-set><pmcid>8482375</pmcid><all-ids><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="pmid">33413710</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="pmc">8482375</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="pii">S1041610220003944</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="doi">10.1017/S1041610220003944</article-id></all-ids><extracted-table><table-id>tbl1</table-id><table-label>Table 1.</table-label><table-caption>Demographic and clinical variables, mean (standard deviation)</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="tbl1" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Demographic and clinical variables, mean (standard deviation)</p></caption><alternatives><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th colspan="1" rowspan="1"/><th colspan="1" rowspan="1">HC (<italic>n</italic> = 31)</th><th colspan="1" rowspan="1">AD (<italic>n</italic> = 29)</th><th colspan="1" rowspan="1">LBD (<italic>n</italic> = 46)</th><th align="left" colspan="1" rowspan="1">Group differences</th></tr></thead><tbody><tr><td rowspan="1" colspan="1" align="center">Male:female</td><td rowspan="1" colspan="1" align="center">22:9</td><td align="center" colspan="1" rowspan="1">20:9</td><td rowspan="1" colspan="1" align="center">34:12</td><td rowspan="1" colspan="1" align="center">χ<sup>2</sup> = 0.23, <italic>p</italic> = 0.89<sup><xref ref-type="table-fn" rid="t1fn1">a</xref></sup></td></tr><tr><td rowspan="1" colspan="1" align="center">Age</td><td rowspan="1" colspan="1" align="center">76.4 (7.2)</td><td rowspan="1" colspan="1" align="center">75.2 (8.6)</td><td rowspan="1" colspan="1" align="center">75.9 (6.9)</td><td rowspan="1" colspan="1" align="center"><italic>F</italic>(2,102) = 0.2, <italic>p</italic> = 0.82<sup><xref ref-type="table-fn" rid="t1fn2">b</xref></sup></td></tr><tr><td rowspan="1" colspan="1" align="center">AChEI</td><td rowspan="1" colspan="1" align="center">–</td><td rowspan="1" colspan="1" align="center">26</td><td rowspan="1" colspan="1" align="center">40</td><td rowspan="1" colspan="1" align="center">χ<sup>2</sup> = 0.01, <italic>p</italic> = 0.92<sup><xref ref-type="table-fn" rid="t1fn3">c</xref></sup></td></tr><tr><td rowspan="1" colspan="1" align="center">PD meds</td><td rowspan="1" colspan="1" align="center">–</td><td rowspan="1" colspan="1" align="center">1</td><td rowspan="1" colspan="1" align="center">33</td><td rowspan="1" colspan="1" align="center">χ<sup>2</sup> = 33.5, <italic>p</italic> &lt; 0.001<sup><xref ref-type="table-fn" rid="t1fn3">c</xref></sup></td></tr><tr><td rowspan="1" colspan="1" align="center">Duration</td><td rowspan="1" colspan="1" align="center">–</td><td rowspan="1" colspan="1" align="center">3.7 (1.7)<sup><xref ref-type="table-fn" rid="t1fn4">d</xref></sup></td><td rowspan="1" colspan="1" align="center">3.2 (2.0)<sup><xref ref-type="table-fn" rid="t1fn5">e</xref></sup></td><td rowspan="1" colspan="1" align="center"><italic>U</italic> = 455, <italic>p</italic> = 0.06<sup><xref ref-type="table-fn" rid="t1fn6">f</xref></sup></td></tr><tr><td rowspan="1" colspan="1" align="center">MMSE</td><td rowspan="1" colspan="1" align="center">28.9 (1.1)</td><td rowspan="1" colspan="1" align="center">21.8 (3.8)</td><td rowspan="1" colspan="1" align="center">22.6 (3.9)</td><td rowspan="1" colspan="1" align="center"><italic>t</italic><sub>73</sub> = 0.9, <italic>p</italic> = 0.39<sup><xref ref-type="table-fn" rid="t1fn7">g</xref></sup></td></tr><tr><td rowspan="1" colspan="1" align="center">UPDRS III</td><td rowspan="1" colspan="1" align="center">1.9 (2.8)</td><td rowspan="1" colspan="1" align="center">3.5 (4.0)</td><td rowspan="1" colspan="1" align="center">20.5 (9.9)</td><td rowspan="1" colspan="1" align="center"><italic>t</italic><sub>73</sub> = 8.8, <italic>p</italic> &lt; 0.001<sup><xref ref-type="table-fn" rid="t1fn7">g</xref></sup></td></tr><tr><td rowspan="1" colspan="1" align="center">CAF total</td><td rowspan="1" colspan="1" align="center">–</td><td rowspan="1" colspan="1" align="center">1.0 (2.5)<sup><xref ref-type="table-fn" rid="t1fn4">d</xref></sup></td><td rowspan="1" colspan="1" align="center">5.5 (4.8)<sup><xref ref-type="table-fn" rid="t1fn8">h</xref></sup></td><td rowspan="1" colspan="1" align="center"><italic>t</italic><sub>69</sub> = 4.5, <italic>p</italic> &lt; 0.001<sup><xref ref-type="table-fn" rid="t1fn7">g</xref></sup></td></tr><tr><td rowspan="1" colspan="1" align="center">NPI total</td><td rowspan="1" colspan="1" align="center">–</td><td rowspan="1" colspan="1" align="center">5.9 (5.5)<sup><xref ref-type="table-fn" rid="t1fn9">i</xref></sup></td><td rowspan="1" colspan="1" align="center">17.2 (11.9)<sup><xref ref-type="table-fn" rid="t1fn5">e</xref></sup></td><td rowspan="1" colspan="1" align="center"><italic>t</italic><sub>69</sub> = 4.6, <italic>p</italic> &lt; 0.001<sup><xref ref-type="table-fn" rid="t1fn7">g</xref></sup></td></tr><tr><td rowspan="1" colspan="1" align="center">NPI hall</td><td rowspan="1" colspan="1" align="center">–</td><td align="center" colspan="1" rowspan="1">0 (0)<sup><xref ref-type="table-fn" rid="t1fn10">j</xref></sup></td><td rowspan="1" colspan="1" align="center">1.9 (1.9)<sup><xref ref-type="table-fn" rid="t1fn5">e</xref></sup></td><td rowspan="1" colspan="1" align="center"><italic>t</italic><sub>68</sub> = 5.0, <italic>p</italic> &lt; 0.001<sup><xref ref-type="table-fn" rid="t1fn7">g</xref></sup></td></tr></tbody></table><graphic xlink:href="S1041610220003944_tab1"/></alternatives><table-wrap-foot><p>Abbreviations: AChEI, number of patients taking acetylcholinesterase inhibitors; AD, Alzheimer’s disease; CAF total, Clinician Assessment of Fluctuation total score; Duration, duration of cognitive symptoms in years; HC, healthy controls; LBD, Lewy body dementia; MMSE, Mini-Mental State Examination; PD meds, number of patients taking dopaminergic medication for the management of Parkinson’s disease symptoms; UPDRS III, Unified Parkinson’s Disease Rating Scale III (motor subsection); NPI, Neuropsychiatric Inventory; NPI hall, NPI hallucination subscore.</p><fn id="t1fn1" fn-type="other"><label>a</label><p>χ<sup>2</sup> test HC, AD, LBD.</p></fn><fn id="t1fn2" fn-type="other"><label>b</label><p>One-way ANOVA HC, AD, LBD.</p></fn><fn id="t1fn3" fn-type="other"><label>c</label><p>χ<sup>2</sup> test AD, LBD.</p></fn><fn id="t1fn4" fn-type="other"><label>d</label><p><italic>N</italic> = 28.</p></fn><fn id="t1fn5" fn-type="other"><label>e</label><p><italic>N</italic> = 44.</p></fn><fn id="t1fn6" fn-type="other"><label>f</label><p>Mann–Whitney <italic>U</italic> test AD, LBD.</p></fn><fn id="t1fn7" fn-type="other"><label>g</label><p>Student’s <italic>t</italic>-test AD, LBD.</p></fn><fn id="t1fn8" fn-type="other"><label>h</label><p><italic>N</italic> = 43.</p></fn><fn id="t1fn9" fn-type="other"><label>i</label><p><italic>N</italic> = 27.</p></fn><fn id="t1fn10" fn-type="other"><label>j</label><p><italic>N</italic> = 26.</p></fn></table-wrap-foot></table-wrap></original-table><transformed-table>Table 1.<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Demographic and clinical variables, mean (standard deviation)</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><colgroup><col/><col/><col/><col/><col/></colgroup><thead><tr><th/><th>HC (n = 31)</th><th>AD (n = 29)</th><th>LBD (n = 46)</th><th align="left">Group differences</th></tr></thead><tbody><tr><td align="center">Male:female</td><td align="center">22:9</td><td align="center">20:9</td><td align="center">34:12</td><td align="center">χ2 = 0.23, p = 0.89???</td></tr><tr><td align="center">Age</td><td align="center">76.4 (7.2)</td><td align="center">75.2 (8.6)</td><td align="center">75.9 (6.9)</td><td align="center">F(2,102) = 0.2, p = 0.82???</td></tr><tr><td align="center">AChEI</td><td align="center">–</td><td align="center">26</td><td align="center">40</td><td align="center">χ2 = 0.01, p = 0.92???</td></tr><tr><td align="center">PD meds</td><td align="center">–</td><td align="center">1</td><td align="center">33</td><td align="center">χ2 = 33.5, p &lt; 0.001???</td></tr><tr><td align="center">Duration</td><td align="center">–</td><td align="center">3.7 (1.7)???</td><td align="center">3.2 (2.0)???</td><td align="center">U = 455, p = 0.06???</td></tr><tr><td align="center">MMSE</td><td align="center">28.9 (1.1)</td><td align="center">21.8 (3.8)</td><td align="center">22.6 (3.9)</td><td align="center">t73 = 0.9, p = 0.39???</td></tr><tr><td align="center">UPDRS III</td><td align="center">1.9 (2.8)</td><td align="center">3.5 (4.0)</td><td align="center">20.5 (9.9)</td><td align="center">t73 = 8.8, p &lt; 0.001???</td></tr><tr><td align="center">CAF total</td><td align="center">–</td><td align="center">1.0 (2.5)???</td><td align="center">5.5 (4.8)???</td><td align="center">t69 = 4.5, p &lt; 0.001???</td></tr><tr><td align="center">NPI total</td><td align="center">–</td><td align="center">5.9 (5.5)???</td><td align="center">17.2 (11.9)???</td><td align="center">t69 = 4.6, p &lt; 0.001???</td></tr><tr><td align="center">NPI hall</td><td align="center">–</td><td align="center">0 (0)???</td><td align="center">1.9 (1.9)???</td><td align="center">t68 = 5.0, p &lt; 0.001???</td></tr></tbody></table></div><div xmlns="http://www.w3.org/1999/xhtml"><img src=""/></div>Abbreviations: AChEI, number of patients taking acetylcholinesterase inhibitors; AD, Alzheimer’s disease; CAF total, Clinician Assessment of Fluctuation total score; Duration, duration of cognitive symptoms in years; HC, healthy controls; LBD, Lewy body dementia; MMSE, Mini-Mental State Examination; PD meds, number of patients taking dopaminergic medication for the management of Parkinson’s disease symptoms; UPDRS III, Unified Parkinson’s Disease Rating Scale III (motor subsection); NPI, Neuropsychiatric Inventory; NPI hall, NPI hallucination subscore.aχ2 test HC, AD, LBD.bOne-way ANOVA HC, AD, LBD.cχ2 test AD, LBD.dN = 28.eN = 44.fMann–Whitney U test AD, LBD.gStudent’s t-test AD, LBD.hN = 43.iN = 27.jN = 26.</transformed-table></extracted-table></extracted-tables-set>